Kura Oncology (KURA) Stock Overview
A clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
KURA Community Fair Values
Create NarrativeSee what 12 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Kura Oncology, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$10.39 |
| 52 Week High | US$12.49 |
| 52 Week Low | US$5.45 |
| Beta | 0.35 |
| 1 Month Change | -4.68% |
| 3 Month Change | 17.67% |
| 1 Year Change | 67.72% |
| 3 Year Change | -0.48% |
| 5 Year Change | -45.17% |
| Change since IPO | -30.73% |
Recent News & Updates
Seeking Alpha • Jul 08
Kura Oncology: A Menin Inhibitor Launch With More Than One Way To Win
Summary Kura Oncology is positioning ziftomenib (KOMZIFTI) as a combination backbone in AML, not just a relapsed/refractory monotherapy. KURA's robust cash position, bolstered by Kyowa Kirin payments, is expected to fund the pivotal KOMET-017 trial through the topline readout in 2028. Recent combination data show high remission rates and tolerability, supporting the platform thesis and expanding addressable AML market potential. I remain optimistic about KURA, focusing on revenue growth, KOMET-017 enrollment, and further combination data to justify a premium valuation. Read the full article on Seeking Alpha
Narrative Update • Jun 23
KURA: Early Launch Execution In AML Will Shape Long Term Prospects
Analysts have modestly lowered their price target for Kura Oncology to about $61 from roughly $63, reflecting updated fair value, discount rate, and profit margin assumptions following recent acute myeloid leukemia market modeling and commercial commentary. Analyst Commentary Recent research on Kura Oncology highlights how the stock is being framed within the evolving acute myeloid leukemia treatment market, especially in relation to other targeted therapy developers.
Narrative Update • Jun 06
KURA: Leukemia And KRAS Trial Progress Will Shape Future Upside Potential
Analysts have trimmed Kura Oncology's average price target by $5 to $15, as recent research updates incorporate revised assumptions on discount rates, revenue growth, profit margins, and future P/E expectations. Analyst Commentary Bullish Takeaways Bullish analysts see room for upside relative to the revised US$15 target, suggesting they still view Kura Oncology's valuation as supported by its pipeline and expected execution, even after more conservative assumptions are applied.Recent updates
Seeking Alpha • Jul 08
Kura Oncology: A Menin Inhibitor Launch With More Than One Way To Win
Summary Kura Oncology is positioning ziftomenib (KOMZIFTI) as a combination backbone in AML, not just a relapsed/refractory monotherapy. KURA's robust cash position, bolstered by Kyowa Kirin payments, is expected to fund the pivotal KOMET-017 trial through the topline readout in 2028. Recent combination data show high remission rates and tolerability, supporting the platform thesis and expanding addressable AML market potential. I remain optimistic about KURA, focusing on revenue growth, KOMET-017 enrollment, and further combination data to justify a premium valuation. Read the full article on Seeking AlphaNarrative Update • Jun 23
KURA: Early Launch Execution In AML Will Shape Long Term Prospects
Analysts have modestly lowered their price target for Kura Oncology to about $61 from roughly $63, reflecting updated fair value, discount rate, and profit margin assumptions following recent acute myeloid leukemia market modeling and commercial commentary. Analyst Commentary Recent research on Kura Oncology highlights how the stock is being framed within the evolving acute myeloid leukemia treatment market, especially in relation to other targeted therapy developers.Narrative Update • Jun 06
KURA: Leukemia And KRAS Trial Progress Will Shape Future Upside Potential
Analysts have trimmed Kura Oncology's average price target by $5 to $15, as recent research updates incorporate revised assumptions on discount rates, revenue growth, profit margins, and future P/E expectations. Analyst Commentary Bullish Takeaways Bullish analysts see room for upside relative to the revised US$15 target, suggesting they still view Kura Oncology's valuation as supported by its pipeline and expected execution, even after more conservative assumptions are applied.Analysis Article • May 15
Analysts Have Lowered Expectations For Kura Oncology, Inc. (NASDAQ:KURA) After Its Latest Results
It's been a good week for Kura Oncology, Inc. ( NASDAQ:KURA ) shareholders, because the company has just released its...Narrative Update • May 03
KURA: Early Leukemia Launch Feedback Will Shape Future Upside Potential
Analysts made a modest upward adjustment to the average price target on Kura Oncology to about $31.17, reflecting updated views on Komzifti's launch feedback, expectations for a shared market, and continued confidence in the long term P/E multiple, even with tempered profit margin assumptions. Analyst Commentary Recent research on Kura Oncology centers on how Komzifti's early launch trends feed into valuation, with analysts adjusting price targets both higher and lower as they factor in Q4 results, launch feedback, and expectations for market share in the r/r NPM1m setting.Narrative Update • Apr 18
KURA: Early Hematology Launch Feedback Will Shape Future Upside Potential
Analysts have reduced their average price target for Kura Oncology by about $1, reflecting updated assumptions on growth, profitability and discount rates, while still citing supportive views regarding Komzifti's launch feedback and its long-term potential in its target indications. Analyst Commentary Recent research shows both supportive and cautious views on Kura Oncology as analysts refresh their models around Komzifti, early launch data, and the company’s broader execution.Narrative Update • Apr 04
KURA: Early Launch Execution And 2026 Guidance Will Shape Long Term Prospects
Analysts have nudged their blended price targets for Kura Oncology slightly lower, trimming fair value by about $0.31 to $62.65. They are factoring in recent Street target cuts in the $15 to $36 range, ongoing support for Komzifti and Revuforj, and modest adjustments to discount rate, revenue growth, profit margin, and future P/E assumptions.Narrative Update • Mar 21
KURA: Early Hematology Launch Execution Will Drive Future Upside Potential
The updated analyst price target for Kura Oncology edges slightly lower to about $32.27 from roughly $32.45, as analysts factor in recent mixed target revisions related to Komzifti's early launch metrics, safety profile, and market share expectations across recent UBS, BofA, Wedbush, and Leerink research. Analyst Commentary Recent Street research on Kura Oncology presents a mixed picture, with price targets moving in both directions as analysts recalibrate around Komzifti's launch metrics, early revenue contribution, and updated financial guidance.Narrative Update • Mar 07
KURA: Komzifti Launch Execution And AML Trial Data Will Drive Upside
The average analyst price target for Kura Oncology has shifted slightly as updates around Komzifti's launch, expected market share, and recent Q4 results have led analysts to fine tune their models, with some lifting targets to levels such as $30 and others trimming them to levels like $20 and $36. Analyst Commentary Recent Street research on Kura Oncology reflects a mix of optimism around Komzifti's launch and caution around execution and competitive dynamics.Narrative Update • Feb 20
KURA: FDA Approval And 2026 Guidance Will Reframe Long Term Prospects
Analysts have reduced their price targets on Kura Oncology by $1 to $5, citing updated models following preliminary Q4 results, Komzifti revenue data, collaboration revenue figures, and the company's 2026 financial guidance. Analyst Commentary Bullish analysts are framing the recent price target revisions as a reset based on updated models rather than a shift in their overall view of Kura Oncology.Narrative Update • Feb 06
KURA: FDA Approval And First Sales Will Reframe Long Term Prospects
Analysts have slightly reduced their fair value estimate for Kura Oncology to about $63 per share, reflecting minor model adjustments after recent price target cuts by firms that updated assumptions around Komzifti revenue, collaboration income, and 2026 guidance following the drug's FDA approval. Analyst Commentary Bullish analysts continue to frame the recent fair value adjustments in the context of Komzifti's FDA approval and the drug's role in Kura Oncology's long term story.Analysis Article • Feb 06
Need To Know: The Consensus Just Cut Its Kura Oncology, Inc. (NASDAQ:KURA) Estimates For 2026
The analysts covering Kura Oncology, Inc. ( NASDAQ:KURA ) delivered a dose of negativity to shareholders today, by...Narrative Update • Jan 23
KURA: FDA Approval And Milestone Payments Will Drive Reassessment Of Prospects
Narrative Update Overview Analysts have adjusted their view on Kura Oncology, with recent price targets ranging from $20 to $30 as they incorporate Komzifti’s FDA approval, updated sales rollout assumptions, preliminary Q4 revenue details, and 2026 guidance into refreshed models. Analyst Commentary Bullish analysts are focusing on Komzifti’s FDA approval and the updated financial framework around the launch as key inputs into their refreshed views on Kura Oncology.Narrative Update • Jan 08
KURA: FDA Approval And Launch Execution Will Drive Future Upside
Analysts raised their price target for Kura Oncology to US$30 from US$29, citing the FDA approval of ziftomenib as Komzifti and updated assumptions around the timing of its commercial roll out. Analyst Commentary Recent commentary around Kura Oncology has focused on how the FDA approval of ziftomenib as Komzifti feeds into the company’s valuation and execution risk from here.Narrative Update • Dec 18
KURA: FDA Approval Will Drive Future Upside Through Emerging Leukemia Franchise
Analysts have modestly raised their price target on Kura Oncology, lifting it to $30 from $29, citing the FDA approval and commercial rollout expectations for Komzifti as key drivers of improved confidence in the company’s long term outlook. Analyst Commentary Analyst reactions to the Komzifti approval have been largely constructive, with modest valuation upside reflecting a more confident outlook on execution and long term growth.Narrative Update • Dec 04
KURA: FDA Approval Will Drive Future Upside From New Leukemia Therapy
Analysts have nudged their price target on Kura Oncology slightly higher, from $29 to $30 per share, citing the FDA approval and rollout expectations for Komzifti as a key value driver. Analyst Commentary Analysts view the FDA approval of Komzifti as a pivotal inflection point for Kura Oncology, prompting upward revisions to valuation models and risk assumptions.Narrative Update • Nov 20
KURA: FDA Approval Will Drive Momentum for New Oncology Therapy Launch
Kura Oncology’s analyst price target has been raised from $27.18 to $31.80, as analysts cite the recent FDA approval of ziftomenib as a key factor that boosts confidence in the company’s growth prospects and financial outlook. Analyst Commentary Bullish Takeaways The recent FDA approval of ziftomenib, branded as Komzifti, is seen as a transformative event.Narrative Update • Nov 06
KURA: Upcoming FDA Decision Will Drive Momentum in Oncology Portfolio
Kura Oncology's fair value price target saw a modest increase from $27.00 to $27.18. Analysts cited updated financial metrics and maintained a cautious outlook following recent peer research coverage.Analysis Article • Nov 03
Is Kura Oncology (NASDAQ:KURA) Weighed On By Its Debt Load?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...Analysis Article • Jul 14
Health Check: How Prudently Does Kura Oncology (NASDAQ:KURA) Use Debt?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Analysis Article • May 07
Analysts Just Shipped A Captivating Upgrade To Their Kura Oncology, Inc. (NASDAQ:KURA) Estimates
Kura Oncology, Inc. ( NASDAQ:KURA ) shareholders will have a reason to smile today, with the analysts making...Analysis Article • May 04
Earnings Update: Kura Oncology, Inc. (NASDAQ:KURA) Just Reported And Analysts Are Boosting Their Estimates
It's shaping up to be a tough period for Kura Oncology, Inc. ( NASDAQ:KURA ), which a week ago released some...
New Narrative • Mar 27
NDA Submission And Trial Progress Will Forge Market Opportunities
Successful NDA submission and accelerated approval paths could enable early market entry, boosting future revenues and earnings.Seeking Alpha • Mar 04
Kura Oncology: The Market Sees A Tough Road Ahead, And I Think There's An Opportunity
Summary Kura Oncology's ziftomenib shows promise in AML treatment, with key data readouts expected in 2025, but faces competition from Syndax's revumenib. Kura's strong cash position supports operations through 2027, bolstered by a lucrative deal with Kyowa Kirin, despite a 50/50 profit share. Market sentiment is low due to second-mover disadvantage and delayed catalysts, but current valuations present a potential buying opportunity. Broader biotech market decline and political uncertainty contribute to Kura's depressed stock price, yet upcoming drug approval could shift momentum. Read the full article on Seeking AlphaAnalysis Article • Mar 04
Industry Analysts Just Upgraded Their Kura Oncology, Inc. (NASDAQ:KURA) Revenue Forecasts By 62%
Celebrations may be in order for Kura Oncology, Inc. ( NASDAQ:KURA ) shareholders, with the analysts delivering a...Seeking Alpha • Jan 23
Kura Oncology: Sentiment Is Too Negative
Summary Kura Oncology's stock plummeted 50% after announcing a collaboration with Kyowa Kirin, making it a less attractive acquisition target despite its promising AML drug candidate ziftomenib. Ziftomenib shows strong potential in treating AML with favorable safety and efficacy profiles, targeting a $7 billion domestic market opportunity. Despite market skepticism, most analysts remain bullish on Kura, with numerous Buy ratings and price targets ranging from $28 to $40 per share. The selloff presents a solid entry point, as Kura trades near pro forma cash with significant milestone payments expected over the next two years. Read the full article on Seeking AlphaSeeking Alpha • Dec 18
Kura Oncology Presents Deep Value At Today's Prices (Rating Upgrade)
Summary Kura Oncology, Inc.'s collaboration with Kyowa Kirin brings $330M upfront and a potential $1.2B in milestone payments, enhancing long-term shareholder value despite initial market disappointment. Ziftomenib, Kura's lead candidate, shows promising results in AML treatment, with a 35% complete remission rate, and could address up to 50% of AML patients. The stock is upgraded to Strong Buy due to its deep value, strong pipeline performance, and potential for substantial upside if FDA approval and commercialization go according to plan. With a robust financial position and promising clinical data, KURA stock offers an asymmetric risk-reward profile, potentially presenting investors with a potentially multifold return. Read the full article on Seeking AlphaSeeking Alpha • Nov 21
Kura Oncology: A Contender In The Field Of Precision Medicine
Summary Kura Oncology's partnership with Kyowa Kirin centered on ziftomenib offers long-term benefits, however, commercialization and significant royalties will take time to materialize. Ziftomenib, Kura's most advanced drug candidate, targets AML with NPM1 mutations, showing promising Phase 1b and a potentially unlocking a $3 billion market in the U.S. Kura's pipeline also includes tipifarnib and KO-2806, but the market remains skeptical of their near-term value, justifying a HOLD rating. Investors should watch for progress in ziftomenib's crucial registration enabling Phase 2 study, or new catalysts from tipifarnib and KO-2806. KURA stock presents deep value at the current price, although the collaboration with Kyowa Kirin will require investors to think long-term and the catalyst for higher prices is not yet clear. Read the full article on Seeking AlphaAnalysis Article • Nov 01
Kura Oncology (NASDAQ:KURA) Has Debt But No Earnings; Should You Worry?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Seeking Alpha • Aug 12
Kura Oncology: The Long Holding Pattern Is Risky
Summary Kura Oncology's menin inhibitor program shows promising results in early studies for AML treatment. Financially, Kura has a good cash position to support upcoming milestones and trials. Competition in the menin inhibitor space poses a risk to Kura's market potential, making valuation uncertain. Read the full article on Seeking AlphaAnalysis Article • Jul 12
Estimating The Fair Value Of Kura Oncology, Inc. (NASDAQ:KURA)
Key Insights Kura Oncology's estimated fair value is US$24.50 based on 2 Stage Free Cash Flow to Equity Kura Oncology's...Shareholder Returns
| KURA | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -2.7% | -1.3% | -1.0% |
| 1Y | 67.7% | 29.0% | 14.7% |
Return vs Industry: KURA exceeded the US Biotechs industry which returned 29% over the past year.
Return vs Market: KURA exceeded the US Market which returned 14.7% over the past year.
Price Volatility
| KURA volatility | |
|---|---|
| KURA Average Weekly Movement | 8.8% |
| Biotechs Industry Average Movement | 10.1% |
| Market Average Movement | 7.1% |
| 10% most volatile stocks in US Market | 16.0% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: KURA has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: KURA's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 260 | Troy Wilson | kuraoncology.com |
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapies in large solid tumor indications; and KO-7246, a next-generation menin inhibitor, for use in diabetes and cardiometabolic disorders and additional next-generation menin inhibitors for use in combination with other therapies in solid tumors. The company is headquartered in San Diego, California.
Kura Oncology, Inc. Fundamentals Summary
| KURA fundamental statistics | |
|---|---|
| Market cap | US$922.37m |
| Earnings (TTM) | -US$294.57m |
| Revenue (TTM) | US$71.64m |
12.9x
P/S Ratio-3.1x
P/E RatioIs KURA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| KURA income statement (TTM) | |
|---|---|
| Revenue | US$71.64m |
| Cost of Revenue | US$260.68m |
| Gross Profit | -US$189.04m |
| Other Expenses | US$105.53m |
| Earnings | -US$294.57m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.32 |
| Gross Margin | -263.88% |
| Net Profit Margin | -411.19% |
| Debt/Equity Ratio | 9.0% |
How did KURA perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/07/27 05:02 |
| End of Day Share Price | 2026/07/24 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Kura Oncology, Inc. is covered by 21 analysts. 14 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Etzer Darout | Barclays |
| Peter Lawson | Barclays |
| Jason Zemansky | BofA Global Research |